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Comparing Efficacy of Denosumab to Bisphosphonates in Fragility Fractures
Abstract
Background: Osteoporosis is a disease of the bones with decreased bone mineral density and
bone mass, leading to poor bone quality/structure, increasing the risk of fragility fractures.
Pharmacological treatment is recommended to decrease risk of fractures. Current first line
treatment is with bisphosphonates; however, alternative treatment includes denosumab. Both
bisphosphonates and denosumab are antiresorptive drugs but differ in mechanism of action.
Bisphosphonates remain as first line treatment.
Purpose: The purpose of this literature review is aimed at the PICO question in adults with
osteoporosis, what is the efficacy of denosumab compared to bisphosphonates in decreasing the
risk of sustaining a fragility fracture? Treatment with bisphosphonates has remained as gold
standard, however, an alternative effective treatment is denosumab. Therefore, the this review
compares the efficacy of denosumab to bisphosphonates and whether this treatment option
should be considered over bisphosphonates.
Methods: A comprehensive literature review was conducted using PubMed. Inclusion criteria
included adult participants (men and women), however, many studies focused on
postmenopausal women given the significant risk for predisposition to osteoporosis. Exclusion
criteria were studies that did not include adults, studies published after 2017, and systematic
reviews.
Conclusions: Based on the literature review, results suggest that the efficacy of denosumab
treatment may be favored over treatment with bisphosphonates in increasing BMD. While
treatment with denosumab increased BMD greater than bisphosphonates, further research/review
should be conducted on the direct effect of fracture reduction with denosumab.
Key Words: osteoporosis, denosumab, bisphosphonates, fragility fracture, postmenopausal
women, osteoporotic fracture, bone mineral density
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Comparing Efficacy of Denosumab to Bisphosphonates in Fragility Fractures
Introduction
According to the NIH, osteoporosis is a chronic and progressive disease of the bones in
which bone mineral density (BMD) and bone mass are severely decreased.1 This leads to
changes in both bone quality and structure, ultimately, increasing the risk of fractures. The NIH
describes osteoporosis as a “silent” disease because individuals typically do not have any
symptoms, thus, many patients are not diagnosed with osteoporosis until they sustain a fracture. 1
One major group with predisposition to increased risk of sustaining fragility fractures, is in
postmenopausal women. Older men are also at risk; however, the risk is higher in
postmenopausal women. A fragility fracture is defined by the International Osteoporosis
Foundation (IOF) as a fracture from low energy trauma and is a sign of underlying osteoporosis.2
The IOF suggests the clinical outcome of osteoporosis is a fragility fracture.2 Furthermore, low
energy trauma is defined as a fall from standing height or less that would not normally result in a
fracture in healthy, non-osteoporotic bone. Areas at greatest risk for fragility fractures in
individuals with osteoporosis include the hip (including femoral fractures), spine, wrist,
humerus, and pelvis.
Studies show the consequences of osteoporosis leading to fragility fractures can have
major consequences on a patient’s quality of life including pain and disability.2 This can lead to
significant loss of independence, as well as significantly increased risk of both morbidity and
mortality. 2 Screening for osteoporosis is identified by the U.S. Preventive Services Task Force
(USPSTF) as a Category B recommendation. 3 Category B indicates the USPSTF found “fair
evidence” to support that a “service,” such as screening for osteoporosis, improves health
outcomes and the benefits outweigh the potential harm. Thus, the USPSTF would
recommendation clinicians to provide that “service.” 3 The IOF identifies treatment of
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osteoporosis to prevent fragility fractures and suggests evidence showing treatment of
osteoporosis with nonpharmacological interventions such as lifestyle factors, as well as
pharmacological intervention.
A study by Rowe et al, suggests that for years, the mainstay pharmacological treatment
for osteoporosis and what has been considered “first line therapy,” has been a class of
medications called bisphosphonates.4 Research discussed by Rowe et al suggests that the use of
bisphosphonates for osteoporosis treatment can increase BMD and reduce both vertebral and
nonvertebral fractures.4 Bisphosphonates are an FDA-approved medication for treatment of
osteoporosis and while there are different medication options within the class of
bisphosphonates, alendronate is often the first line option due to a broad spectrum of antifracture
efficacy and its low cost. A study by Rogers et al, discusses the mechanism of action for
bisphosphonates.5 According to Rowe et al, over the years, there has been a large amount of
evidence supporting the use and efficacy of bisphosphonates on hip fracture prevention, as well
as vertebral and nonvertebral fractures, therefore, current guidelines suggest bisphosphonates as
first line therapy for osteoporosis.4
However, years later, in 2010, a new class of pharmacological treatment for osteoporosis
was release, denosumab. While the mechanism of action for bisphosphonates and denosumab
defer, both classes of medication for treatment of osteoporosis are FDA-approved. Both
bisphosphonates and denosumab are antiresorptive therapies, however, the mechanism of action
defers in that the bisphosphonate acts by binding the mineral component of bone, thus,
interfering with the action of osteoclasts.6 On the other hand, denosumab are antiresorptive
medications but are fully human monoclonal antibodies that bind to cytokine receptor activator
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of NFkB ligand and are essential for initiating bone turnover. This leads to loss of osteoclasts,
which are bone cells responsible for bone resorption, from bone surface.6
A PICO question was identified for the purpose of this literature review. The purpose of
this literature review is to understand and make recommendations if treatment with denosumab is
more efficacious in decreasing the risk of sustaining a fragility fracture compared to treatment
with bisphosphonates in adults with osteoporosis. In order to answer the research PICO question,
the literature review requires separation into different sections for better flow of understanding.
First, research of studies was required to show the importance of osteoporosis as it relates to
fragility fractures and the ongoing health care gap for the treatment of osteoporosis. Current
literature supporting first line treatment for osteoporosis with bisphosphonates will be discussed,
followed by a discussion of studies focused on treatment with denosumab, as to compare
evidence that supports both pharmacological treatment options.6 This will help entail a
comprehensive discussion to analyze differences in both pharmacological treatment options for
osteoporosis and their efficacy in decreasing the risk of fragility fractures.
Methods
A comprehensive literature review was conducted for research and for analysis of the
PICO question. Initial research was conducted to understand osteoporosis and associated risk of
fragility fractures. Then research was focused primarily on pharmacological treatment of
osteoporosis to directly prevent risk of sustaining a fragility fracture. The main search engine
utilized in for literature review was PubMed with key words and terms including “osteoporosis,
fracture risk, fragility fracture, osteoporotic fracture, bisphosphonates, and denosumab.”
Inclusion criteria were studies that discussed treatment with bisphosphonates, denosumab, or
both for osteoporosis. Additionally, inclusion criteria included adults with osteoporosis or adults
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who were at risk of osteoporosis, children and adolescents were not included. Both women and
men were included in the literature review. Exclusion criteria were studies published before 2017
and systematic reviews.
Review of Literature
Background and Significance
Osteoporosis increases the risk of sustaining a fragility fracture. Osteoporosis is a
metabolic bone disease in which there is low bone density and deterioration of bone architecture.
According to Tu et al, osteoporosis-related fractures can lead to debilitating and significant
lifestyle changes including increased pain, possible nursing home placement increased costs, and
increased mortality.7 Therefore, treatment for osteoporosis is recommended to prevent risk of
fractures. Tu et al discuss osteoporosis medication options, including bisphosphonates and
denosumab.7 They discuss the limitations in research and a definitive “gold standard” for
treatment for osteoporosis. Complications of evidence-based research have recommendations for
pharmacological treatment of osteoporosis with various options in various populations, however,
there is a lack of consensus to what exactly this “gold standard” treatment entails. The mainstay
of osteoporosis treatment for years has been bisphosphonates, however, many years after initial
approval from FDA for bisphosphonates, another osteoporosis medication, denosumab, was also
approved. According to Tu et al, there are inconsistencies as to where to place denosumab in the
guidelines.7
Lorentzon discusses the importance of treating osteoporosis to prevent fractures.8 This
study provides a wealth of background information on the significance of osteoporosis and its
association with fragility fractures. Antiresorptive drugs are the most commonly used
medications targeted at treatment for osteoporosis, these include both bisphosphonates and
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denosumab. As discussed earlier, the mechanism of action of antiresorptive drugs is to increase
BMD. Antiresorptive drugs are the preferred osteoporosis treatment option because increasing
BMD translate to decreasing fractures. Despite recognized benefits of pharmacological treatment
for osteoporosis with antiresorptive medications such as bisphosphonates and denosumab,
Lorentzon discusses the lack of treatment that patients receive regardless of the proven efficacy
of pharmacological treatment for osteoporosis.8 Additionally, research shows evidence that
supports effectiveness of increasing treatment for osteoporosis to reduce fracture risk and rates.
Bisphosphonates continue to be the most widely used medication for osteoporosis treatment
which work by reducing the rate of bone remodeling done by inhibiting osteoclast activity, thus
bone resorption.5-6 Like many studies, Lorentzon identifies bisphosphonate therapy as the first
line treatment choice for osteoporosis.8 However, this study also identifies denosumab as another
comparable treatment option. denosumab is recognized as the most potent antiresorptive agent
for osteoporosis treatment and is classified as a monoclonal antibody to the receptor activator of
nuclear factor-kB ligand (RANKL), which is a key regulator of bone resorption on osteoclast
development, function, and survival.6 Limitations in evidence and research are identified for
comparing bisphosphonates and denosumab in the current choice of osteoporosis treatment given
increasing evidence for efficacy of denosumab in increasing bone mineral density.6
The comprehensive literature review of multiple studies will first begin with
understanding the importance of osteoporosis, fragility fractures, and treatment for osteoporosis.
The review will discuss measuring the efficacy of osteoporosis treatment with BMD, followed
by studies that compare treatment with bisphosphonates and denosumab.
Osteoporosis and fragility fractures
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It is important to understand the importance of osteoporosis and its impact on the risk of
fragility fracture. Initial studies were reviewed to understand the impact of a fragility fracture,
thus would justify importance of osteoporosis treatment initiation. A research study by Bell et al,
performed a retrospective observational study on the management of osteoporosis after a fragility
fracture in a primary care setting.9 Researchers identified the osteoporosis health care gap
including lack of osteoporosis treatment in patients who had already sustained an initial fragility
fracture, thus, were diagnosed with osteoporosis. Bell et al concluded that after patients had
sustained an initial fracture, 60.2% remained untreated for osteoporosis.9 Furthermore,
researchers also concluded that 62.2% of patients who sustained subsequent fractures, remained
untreated. Another 83.2% of patients who had sustained an initial fragility fracture did not have a
fracture risk assessment (FRAX) performed. Bell et al strengthen support for the ongoing care
gap in osteoporosis treatment, therefore increasing risk of fragility fractures.9 The results
concluded in this study suggest that osteoporosis and fragility fractures are not recognized as
major risk factors that prompt intervention with treatment. Multiple studies focused on research
that demonstrate and conclude that treatment of osteoporosis with pharmacological treatment
with bisphosphonates and denosumab does in fact increase bone mineral density, thus, decreases
risk of fragility fractures.
In a study by Barrionuevo et al, efficacy of pharmacological treatment for osteoporosis
on fracture prevention is discussed.10 The goal of this study was to determine and compare the
effectiveness of various pharmacological treatments for osteoporosis, including bisphosphonates
and denosumab, among other therapies. However, for the purpose of this literature review with a
focused PICO question, bisphosphonates and denosumab are the primary medications to be
reviewed based on study results. Barrionuevo et al included 107 trials, which included a total of
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193,987 postmenopausal women.10 This was a meta-analysis study, ultimately an initial strength
of the study was the large sample size included. Randomized controlled trials with inclusion
criteria for postmenopausal women with primary osteoporosis were included and evaluated in
this study.10 Risk of sustaining a hip, vertebral, or nonvertebral fracture were evaluated.
Barrionuevo et al.8 concluded that there were significant reductions in hip fractures in
participants who were treatment with various bisphosphonates, denosumab, estrogen with
progesterone, and a combination of calcium with vitamin D. For evaluation of nonvertebral
fractures, there was a significant reduction with treatment of various bisphosphonates,
denosumab, estrogen with progesterone, vitamin D, and teriparatide. And finally, for vertebral
fractures, there was significant reduction with treatment again with various bisphosphonates,
denosumab, estrogen with progesterone, teriparatide, and more treatment options. Barrionuevo et
al suggest that the highest relative risk reductions for fractures in those treated for osteoporosis
with teriparatide and denosumab, among two additional options.10 However, of these suggested
conclusions, bisphosphonates were not identified in the highest fracture risk reduction.
One key factor in this literature review to answer the PICO question is how efficacy of
pharmacological treatment would be measured. According to Rothman et al, the best way to
monitor osteoporosis treatment is with BMD, thus, in order to answer the PICO question,
efficacy of denosumab and bisphosphonate therapy would be measured based on measurement of
BMD.11 BMD assessment can be measured by DEXA and is the most widely available and
validated clinical tool to measure BMD.11
Treatment with Bisphosphonates
Treatment with bisphosphonates was initially reviewed prior to study evaluation of
denosumab as the current first line treatment recommendations are suggested to be with
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bisphosphonates. It is important to understand why the research and evidence of why
bisphosphonates have shown proven efficacy in treatment of osteoporosis to increased BMD and
decrease fracture risk. A study by Black et al discusses the use of bisphosphonates on atypical
femur fracture risk compared to fragility fracture prevention.12 Researchers initially recognize
that bisphosphonates have been identified as first line treatment for osteoporosis, therefore, states
that bisphosphonates are effective in specifically reducing hip fractures and overall, fragility
fractures. Furthermore, researchers identify previous research in support that bisphosphonates
have established efficacy in ability to increase bone mineral density and decrease the risk of
fractures by at least 40 to 70%.12
Through the years since bisphosphonates were approved by the FDA, reported cases in
unusual fragility fractures, specifically, subtrochanteric fractures along the femoral diaphysis,
were identified have been caused by use of bisphosphonates. Black et al researched the
uncertainties of bisphosphonates in risk of subtrochanteric femur fractures.12 They concluded
that the risk of atypical femur fractures was increased with prolonged duration of bisphosphonate
treatment, however, the absolute risk of these fractures remained low. Recommendations remain
aligned with current research that treatment with bisphosphonates to prevent fragility fractures
outweigh the small risk of sustaining a bisphosphonate related subtrochanteric femur fracture.
Black et al, state the reduction of risk in hip and other fractures remains low.12 One strength of
this study is the large sample size, which included 196,129 women. However, there are also
limitations in this study including the majority of patients taking one specific bisphosphonate
medication, Alendronate. Therefore, study results are limited to understand the overall
conclusion that the benefit of all bisphosphonate treatment would outweigh the risk of sustaining
an atypical bisphosphonate-related femur fracture.
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Another study by Byun et al, researched the efficacy of bisphosphonates specifically for
the prevention of osteoporotic fractures.13 Researchers conducted a meta-analysis to update the
knowledge of bisphosphonates used as first line treatment of osteoporosis and to reduce fracture
risk. Comparison of twenty-four randomized controlled trials were investigated to compare the
effects of bisphosphonates used in preventing osteoporotic fractures.13 A final analysis concluded
evidence that supports use of bisphosphonates decreased the overall risk of patients sustaining a
fragility fracture including both vertebral and nonvertebral fractures. While this study supports
previous research and evidence that use of bisphosphonates decreased risk of osteoporotic
fractures. Compared to the research study conducted by Black et al, this study included different
bisphosphonates rather than Alendronate alone.12 Byun et al included results after evaluating
efficacy of bisphosphonates including Alendronate, Risedronate, Etidronate, Zoledronic Acid,
Clodronate, Ibandronate, Minodronate, and Pamidronate.13 One major limitation of the study is
that while there is an overall conclusion for evidence that supports bisphosphonates can
effectively reduce the risk of fragility fractures, there was limited evidence on the efficacy of one
bisphosphonate, Etidronate.
Rowe et al discusses bisphosphonate therapy for treatment of osteoporosis in
postmenopausal women.4 This study provides detailed information on the background of
osteoporosis, guidelines for osteoporosis including screening, and use of bisphosphonate therapy
for fracture prevention. Bisphosphonates have been considered first line therapy worldwide for
treatment of osteoporosis and for primary prevention of fractures.4 Rowe et al, discuss treatment
with bisphosphonates in more detail, including research that shows bisphosphonates are the most
prescribed pharmacological treatment for osteoporosis.4 The FDA approved multiple
bisphosphonates for treatment of osteoporosis. Alendronate is preferred and tends to be the
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primary choice of selection because it has a broad spectrum of efficacy in antifracture and low
cost. Rowe et al discuss wide variety of evidence that support the efficacy of oral bisphosphonate
treatment associated with preventing hip fractures.4 Duration for treatment with bisphosphonates
is discussed suggesting that continuing bisphosphonate treatment for up to 10 years showed
continued benefits. While there is recognized risk with continuing bisphosphonate therapy
without a known drug holiday, overall, this risk should be assessed individually for patients.
Increased duration of bisphosphonates increases the risk of atypical factures and osteonecrosis of
the jaw. Similar to the study by Black et al, the risk of atypical femur fractures is recognized with
increased duration of bisphosphonate treatment, however, ultimately, individuals should be
assessed to weight the benefits versus risks.12
Treatment with Denosumab
After reviewing the efficacy of bisphosphonates on BMD, review of treatment with
denosumab on BMD was conducted for comparison. While research supports bisphosphonates as
first line treatment of osteoporosis, denosumab was approved by the FDA in 2010 as an
alternative option for treatment of osteoporosis. Chen et al study the efficacy and safety of
denosumab for osteoporosis in postmenopausal women.14 The aim of the study was to
understand the evidence in support of use of denosumab on osteoporosis. Researchers conducted
a meta-analysis, only including randomized controlled trials that reported efficacy of denosumab
for treatment of osteoporosis. Inclusion factors for studies included postmenopausal women who
had been diagnosed with osteoporosis or low bone mineral density. Chen et al, concluded that in
patients who used denosumab, the percentage change of bone mineral density was greater
compared to the group who did not take denosumab in all areas of interest including radius,
femoral neck, lumbar spine, total hip, trochanter, and total body.14 Results were statistically
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significant concluding that denosumab therapy significantly reduced the risk of clinical fractures
without excess risk of adverse events. One limitation in the study by Chen et al for the purpose
of this literature review, was that researchers only studied the effects and results of denosumab.14
There was no comparison in this study to other classes of medication for osteoporosis.
In a study by Zhang et al, treatment of osteoporosis with denosumab was reviewed
including both pros and cons of medication use.15 Researchers identify denosumab as a “novel
human monoclonal antibody for osteoporosis,” which ultimately helps to decrease osteoclastmediated bone resorption and turnover. In turn, this helps to increase bone mineral density and
can subsequently decrease risk of fragility fractures. Zhang et al identify adverse of events from
pharmacological treatment with denosumab including skin eczema, flatulence, cellulitis, and the
most concerning, osteonecrosis of the jaw.15 Furthermore, research shows that denosumab may
amplify a patient’s skin allergy or inflammatory response, thus increases susceptibility to
infections. While there are possible adverse effects of denosumab, on the other hand, Zhang et al
also identify the benefits and proven efficacy of treatment with denosumab for osteoporosis and
fracture reduction.15 Researchers discuss clinical data and evaluation of significant increase of
bone mineral density at the lumbar spine and hip joints with denosumab treatment. According to
Zhang et al, they identified a study which showed denosumab decreased risk of vertebral
fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20%.15 Similar to the
study by Chen et al, denosumab was suggested to reduce risk of fracture at similar sites.14-15 The
difference between the studies was that Zhang et al only discussed fracture reduction at three
sites with broad sites at risk for fractures.
Comparing Bisphosphonates and Denosumab
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This literature review is focused on answering the PICO question of comparing efficacy
of denosumab and bisphosphonates on fracture reduction, thus, the transition from evaluating
bisphosphonates and denosumab separately should be combined to directly understand
differences and evidence-based results on comparing the efficacy of two pharmacological
options on BMD and reduction of risk of fractures.
Another study by Wu et al, differed from the study by Chen et al in that they directly
compared denosumab to bisphosphonates for treatment of osteoporosis in postmenopausal
patients.14,16 Researchers conducted a meta-analysis to compare the efficacy and safety of both
medications, as they are the two most common pharmacological treatment options for
osteoporosis. A total of 5446 patients were included in the study.16 A strength of this study was
that patients were divided closely for those who took denosumab versus bisphosphonates. 2873
patients involved were treated with denosumab and 2573 were treated with bisphosphonates.
Interestingly, researched concluded that there was no significant different between the two
treatments in the risk of fracture or adverse events. Researchers suggested that results support
that denosumab significantly increased change in hip, femoral neck, lumbar spine, and radius
bone mineral density in postmenopausal osteoporotic patients.
This conclusion similarly aligns with results by Wu et al, who focused primarily on
efficacy of denosumab in that both studies concluded that denosumab does in fact increase bone
mineral density at multiple sites at risk for fragility fracture.16 While Chen et al, suggested that
denosumab reduced the risk of fractures, this study by Wu et al was unable to concluded that
there was a reduction of fracture risk with denosumab when compared to bisphosphonates.14,16
In a similar study conducted by Miller et al, researchers studied the efficacy and safety of
denosumab compared to bisphosphonates in postmenopausal women who had previously
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received treatment for osteoporosis with oral bisphosphonates.17 Both studies compared both
medications, as well as specifically included postmenopausal women as inclusion criteria.
However, the purpose of the study by Miller et al was to understand use of denosumab after
patients had already received initial oral bisphosphonates.17 A total of 2850 randomized patients
were included in the study, 1424 of which took bisphosphonates, and the remaining 1426 took
denosumab. Researchers focused on measurement of bone mineral density from a baseline
measurement compared to 12 months after initiation of treatment.17 One group was treated with
denosumab after participants were identified as meeting inclusion criteria for previously being
treated with oral bisphosphonates, while the comparison group continued to take
bisphosphonates during the study. Researchers concluded that there was a significant increase in
bone mineral density in patients who transitioned to denosumab compared to those who
continued to take oral bisphosphonates. Discussion of this finding should be compared to the
study by Wu et al who also compared the efficacy of denosumab and bisphosphonates but
concluded that they did not have any significant difference between the two treatments in the risk
of fractures.16
Bouxsein et al studied the change in bone mineral density and its direct effect on
reduction in fracture risk.18 Through a meta-regression including 38 controlled trials, researchers
concluded that improvement in bone mineral density, as measured by results from dual-energy
X-ray absorptiometry (DXA), were associated with reduction in risk of sustaining fractures.
Researchers specifically analyzed the risk reduction at three primary sites for fractures including
vertebral, nonvertebral, and hip.18 A total of ten different osteoporosis treatment classes were
included in this study, of the ten treatment options, bisphosphonates and denosumab were
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included.18 One limitation of this study is that researchers suggested results on limited to
vertebral and hip fractures.
Reviewing the suggested conclusion of results by Bouxsein et al in that increased bone
mineral density does in fact decrease risk of fractures, this can be translated to both studies by
Wu et al and Miller et al, who specifically compared denosumab and bisphosphonate treatment
for osteoporosis in postmenopausal women.16-18 Although both these studies do not directly
conclude or suggest that there was a significant reduction in risk of fracture, both studies suggest
that there is an increase in bone mineral density in patients who are treated with denosumab
compared to bisphosphonates. The results of Bouxsein et al, suggest that when there is increase
bone mineral density as a result of pharmacological treatment with denosumab for osteoporosis,
this will decrease the risk of a patients’ risk for a fragility fracture.18
A retrospective study by Augoulea et al, compared the effects of treatment with
denosumab to bisphosphonate on bone mineral density and calcium metabolism.19 113
postmenopausal women were included in this study and participants either received treatment
with denosumab or bisphosphonates for 12 months. Bone mineral density was measured using
DXA measurements at the lumbar spine and femur. Baseline measurements were compared to
follow up at 12 months after treatment. Results from this study showed that bone mineral density
at the femoral neck increased in both groups who received treatment with denosumab and
bisphosphonates. When evaluating the lumbar spine, only the treatment group who received
denosumab showed significant increase in bone mineral density. Furthermore, Augoulea et al,
suggested that while both treatments with denosumab and bisphosphonates increased bone
mineral density in the femoral neck, denosumab demonstrated higher increase from baseline. 19
Researchers also concluded that treatment with denosumab increased serum parathyroid
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hormone, but baseline vitamin D levels did not change. One major limitation in this study by
Augoulea et al.16, was the small sample size of only 113 participants. This differs from
previously discussed literature with significantly larger sample sizes such as studies from Miller
et al., Wu et al., and Chen et al which all showed similar outcomes which supported similar
conclusions when comparing denosumab and bisphosphonates.14,16-17 The outcomes of these
studies concluded that denosumab increased BMD when compared to bisphosphonates in
postmenopausal women.
A study by Lyu et al, compared denosumab and bisphosphonates to determine if one
pharmacological treatment for osteoporosis was more effective than the other. 20 More
specifically, the goal of the study for researchers was to determine if denosumab was more
effective compared to bisphosphonates in increasing bone mineral density and reducing fracture
risk for patients who had known low bone mineral density or diagnosed with osteoporosis.
Researchers conducted a meta-analysis with a total of 5361 participants. One limitation of the
study by Lyu et al was that while inclusion criteria did not exclude men from the studies,
researcher reported that 99% of the participants in the study were women.20
Compared to many other studies including Chen et al, Wu et al, Miller et al, these studies
utilized inclusion criteria targeted at postmenopausal women, as this group is at increased risk of
osteoporosis, therefore, at increased risk of sustaining a fragility fracture.14,16-17 The limitation of
the study by Lyu et al is minimal inclusion of men when there were no specific exclusion criteria
that limited men from being studied.20 Lyu et al identified 1533 participants who had no prior
osteoporosis treatment, 714 who had previously sustained a fracture, 2914 who had previously
received bisphosphonate treatment prior to the study, and 200 who receive teriparatide prior to
the study.20 The majority of results were collected and studied for participants after receiving
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treatment for 12 months with either denosumab or bisphosphonates. Those who took
bisphosphonates included multiple different medications within the class, similar to the study by
Byun et al. This is a strength of this study, as well as the study by Byun et al, as they included
multiple medications with the class, thus, researchers from both studies had more evidence to
support their conclusions.13 Lyu et al concluded that at 12 months, denosumab increased bone
mineral density more than bisphosphonates at multiple sites including lumbar spine, total hip,
and femoral neck.20 While denosumab increased bone mineral density more than treatment with
bisphosphonates, researchers did not see any different in fractures for patients within 12 months.
One finding Lyu et al reported was a lower incidence of osteoporotic fracture in patients who
took denosumab compared to alendronate, a specific bisphosphonate at 24 months. 20
A study by Kocjan et al was reviewed after the study by Lyu et al.20-21 This study directly
researched the use of denosumab compared to bisphosphonates in postmenopausal women with
severe osteoporosis after they had previously completed treatment with teriparatide. While Lyu
et al. had some discussion with use of Teriparatide, their study was limited by a small sample
size of 200 in such a large sample from the study of 5361 participants who were on teriparatide,
therefore, there were minimal conclusions for denosumab versus bisphosphonate after
teriparatide therapy.20
Kocjan et al specifically studied patients who had already completed treatment with
teriparatide in this retrospective study who would follow this treatment with either denosumab or
bisphosphonates.21 Bone mineral density was compared after 12 months of treatment with either
osteoporosis treatment in postmenopausal women after stopping or completing teriparatide
therapy. Researchers compared bone mineral density at multiple sites including lumbar spine,
total hip, and femoral neck using DEXA scan. Baseline DEXA scans were completed once

Toledo Cardoso 20
teriparatide therapy was discontinued, then measured again at 12 months to compare in each
participant. Results of the study showed that only lumbar spine bone mineral density had a
significant increase in the group who took denosumab after teriparatide therapy compared to the
group who took bisphosphonates.21 There was no clear indication of any difference in total hip or
femoral neck bone mineral density. There were significant limitations in this study including an
extremely small sample size. While it was identified that the sample size of participants who
took teriparatide in the study by Lyu et al was small, the sample size in this study was even
smaller with only 140 postmenopausal women.20 One strength of the study was separating the
sample size of both groups equally to 70 participants. Results from this study only yielded a
higher bone mineral density in the lumbar spine and did not show significant results from the
total hip or femoral neck. This is different compared to previously studies including studies by
Chen et al, Wu et al, and Lyu et al, which all saw increased bone mineral density at multiple sites
as a resulted of treatment with denosumab.14,16,20
Another study reviewed by Pedersen et al, who conducted a cohort study of 92,355
participants whose objective was to compare the risk of a hip fracture in patients who were
treated with denosumab compared to alendronate (a bisphosphonate).22 Researcher included
4,624 who were treated with denosumab and 87,731 who were treated with alendronate. The
cohort study occurred over the course of three years. Similar to the study by Lyu et al, the
majority of participants in this study was women even though researchers did not exclude men.
81.3% of participants were women between the two groups, with the denosumab group having a
lower proportion of men.20,22 The measuring outcome was hip fracture including both primary
and secondary diagnoses. Pedersen et al concluded that in comparing osteoporosis treatment with
denosumab versus alendronate, there was similar associated risk for osteoporotic fractures over a
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period of three years.22 One limitation of this study was that researchers lacked any measurement
of frailty, socioeconomic status, or lifestyle for the participants, leading to possible bias and
affected results.
Discussion and Analysis
After performing a literature review guided by the initial PICO question, many research
studies show significant results in comparing efficacy of denosumab and bisphosphonates in the
treatment of osteoporosis. Based on fifteen studies included in the literature review, a general
consensus obtained from analysis of each study suggests that overall, treatment of osteoporosis
with denosumab compared to the class of pharmacological treatment with bisphosphonates, was
greater when analyzing BMD in patients. Studies were reviewed in a strategic order in order to
fully comprehend the results and organization to reach conclusions for the PICO questions. First,
general background information was presented and reviewed, followed by understanding the
efficacy of bisphosphonates, as they have been previously recognized as “first line treatment.”
Studies that focused primarily on treatment with denosumab showed the efficacy of denosumab
with successful results. Mutliple studies were included in the review that showed comparison of
denosumab and bisphosphonates. This sequence of review is important to understand the shift of
evaluating the efficacy of denosumab and perhaps showing
An initial study by Rothman et al was reviewed to understand the best way to monitor
osteoporosis treatment, thus, be a measurement for the efficacy of pharmacological treatment. 11
A study by Rothman et al concluded the best way to monitor osteoporosis treatment is by
measuring bone mineral density with a DEXA scan to see an increase in BMD, therefore this
was used to measure the efficacy of denosumab and bisphosphonates.
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In the discussion of osteoporosis background prior to multiple research studies,
bisphosphonates were identified by researchers as the established first line treatment of
osteoporosis compared to denosumab. There was a consensus from five studies that included
discussion of both denosumab and bisphosphonates, that postmenopausal women were at
greatest risk for osteoporosis, therefore, this population required osteoporosis treatment with
pharmacological option. Inclusion criteria of these studies was postmenopausal women.14,1617,19,21

Literature review of studies that solely focused on evaluating efficacy of bisphosphonates
was evaluated initially given that previous evidence suggests that the first line treatment of
osteoporosis is with bisphosphonates. Three studies were reviewed that evaluated efficacy of
bisphosphonates on fracture reduction and results on BMD. Results from two of the three studies
primarily focused on bisphosphonates concluded that there was an overall risk reduction of
fractures, as well as increased BMD. A study by Black et al, focused on bisphosphonates and the
risk of atypical subtrochanteric femur fractures as a result of bisphosphonate treatment. 12
Researchers concluded that the risk of fragility fractures outweighed the small risk of sustaining
a bisphosphonate related atypical femur fracture, thus the recommendation based on results was
to use bisphosphonates for osteoporosis treatment. Two additional studies were reviewed, these
focused on the efficacy of denosumab on similar outcomes for increased BMD and fracture risk
reduction. The two studies only including denosumab showed that there were significant
increases in BMD after treatment. These results show that there is translation that increased
BMD from treatment of denosumab will decrease risk of fractures.
After literature was reviewed separately for both denosumab and bisphosphonates,
additional literature was compiled for review to directly compare the two classes of
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pharmacological treatment for osteoporosis. Seven studies were reviewed that compared
denosumab with bisphosphonates. Six of the seven studies that compared denosumab directly to
bisphosphonates in their efficacy for the treatment of osteoporosis, came to a general consensus
that treatment with denosumab showed increased BMD compared to treatment with
bisphosphonates. Of the studies that reported increased BMD with osteoporosis treatment, all
concluded increased BMD with denosumab over bisphosphonates. This shows efficacy of
denosumab seems to be greater compared to bisphosphonates in increasing BMD.
With results of six of the seven studies comparing denosumab to bisphosphonates with
reported outcomes for increased BMD favoring treatment with denosumab, selecting treatment in
patients with osteoporosis need to be reconsidered. Denosumab may be the preferred treatment
option to reduce risk of patients sustaining fragility fractures after 12 months of treatment due to
successful treatment and increased BMD.
One major strength of the literature review is that multiple meta-analysis studies were
included, thus, strengthening the generalizability of the results. Given multiple meta-analysis
studies, another strength from these studies is the large sample size population in each study that
helps to strengthen the accuracy and validity of evidence-based results. An additional strength of
the literature review includes studies that directly align with the initial PICO question in
comparing the efficacy of denosumab and bisphosphonates for treatment of osteoporosis. The
study by Lyu et al directly aligns with the PICO question for this literature review in that
researchers compared denosumab and bisphosphonates to determine which pharmacological
treatment of osteoporosis would be more effective in increasing bone mineral density and
reducing fracture risk.20 Lyu et al concluded that treatment with denosumab significantly
increased bone mineral density at multiple “at risk” fracture sites compared to bisphosphonates. 20
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The results of this study, along with conclusions from additional studies included in the literature
review, all suggest increased BMD with denosumab. With increased BMD, Rothman et al
suggest this as a predictor for monitoring the efficacy of osteoporosis treatment. When BMD is
increased, there is an association with decreased risk of fractures.11
The study by Pedersen et al compared denosumab to one specific bisphosphonate
medication, alendronate.22 This study did not align with the remaining six studies that compared
denosumab to bisphosphonates, as researchers measured efficacy of pharmacological treatment
with hip fracture outcomes. Pedersen et al concluded that there was no major difference in hip
fracture outcome when comparing the group who were treated with denosumab versus
alendronate.22 While this study showed no significant conclusions favoring one treatment over
the other, six additional studies support the conclusion that denosumab seems to be favored
treatment over bisphosphonates for increasing BMD in patients with osteoporosis.
Drawing an overall conclusion based on evidence from multiple research studies, that
denosumab increases BMD at multiple sites compared to bisphosphonates, this can be further
translated to suggest that there is fracture risk reduction with denosumab. After analysis of
multiple literature studies, evidence shows that the efficacy of denosumab compared to
bisphosphonates on BMD seems to favor denosumab. There were significant increases in BMD
with treatment of denosumab when directly compared to bisphosphonates.
On the other hand, there were some studies that utilized smaller sample size populations,
which is a considered a limitation as it makes it more difficult to draw confident conclusions to
generalize the outcomes and findings. Another limitation of literature review for the initial PICO
question was a lack of study that included all areas of interest including the efficacy of
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denosumab compared to bisphosphonates, measurement of efficacy with BMD, and specific data
on decrease in fragility fractures.
Conclusion
The initial PICO question prior to the literature review was to understand that in adults
with osteoporosis what the efficacy of denosumab compared to bisphosphonates would be in
decreasing risk of sustaining a fragility fracture. Osteoporosis is a disease of the bones that leads
to decreased BMD and bone mass, ultimately effecting bone quality leading to significantly
increased risk of sustaining a fragility fracture. While denosumab is not considered the first line
treatment, like bisphosphonates, it has shown to be an effective osteoporosis treatment option
that increases BMD. When BMD is increased, evidence shows a positive correlation to reduction
of fractures. Therefore, denosumab should be evaluated further compared to bisphosphonates as
to understand whether the treatment option may have greater efficacy on fracture reduction.
A thorough and strategic literature review was performed including multiple research
studies that compared efficacy of denosumab to bisphosphonates based on measurement of
BMD, to reach conclusions for the PICO question. Efficacy of treatment with denosumab versus
bisphosphonates was measured by increase in BMD at multiple sites. Overall, after review of
literature, the initial PICO question was partially answered in that research shows favored
efficacy of denosumab treatment in increasing BMD for patients with osteoporosis. However,
after review of literature, there is no evidence as to direct results for decreasing a patient’s
specific risk of sustaining a fragility fracture. Additional research and review of studies should
be performed to understand specific data on the risk of fractures after treatment with denosumab
and bisphosphonates. While studies from this literature review did imply that there is likely a
decreased risk of fractures based on increased BMD at multiple sites, there was a lack of specific
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data on what percentage of fractures was decreased. It is still unclear as to whether there are
studies that directly compare denosumab and bisphosphonates that show a percentage decreased
in sustaining a fragility fracture. Additional research should be conducted to understand the
efficacy of denosumab compared to bisphosphonates on fracture reduction with data supporting
percentage decrease.
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